Minhai Biotechnology and the Chongqing Center for Disease Control and Prevention have signed a strategic cooperation agreement to support the development of public health.

Release date:

2025-03-14

Author:

Source:


Abstract

On the afternoon of March 11, 2025, Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as “Minhai Bio”) and the Chongqing Center for Disease Control and Prevention (hereinafter referred to as “Chongqing CDC”) successfully held a cooperation and exchange meeting at Minhai Bio’s Internationalization Industrial Base for Novel Vaccines. The meeting was attended by senior company executives, including Zhang Huadong, Director of the Chongqing CDC; Ji Hengqing and Wang Qing, Deputy Directors; and Zheng Haifa, General Manager of Minhai Bio, along with Liu Jiankai, Executive Deputy General Manager and Director of the R&D Center. During the event, Minhai Bio’s heads of R&D and clinical operations presented the company’s development history, its innovative R&D capabilities, and the progress of clinical trials for key projects.

 2025 Year 03 On the afternoon of the 11th, Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as “Minhai Bio”) and the Chongqing Center for Disease Control and Prevention (hereinafter referred to as “Chongqing CDC”) successfully held a cooperation and exchange meeting at Minhai Bio’s Internationalization Industrial Base for Novel Vaccines. The meeting was attended by senior company executives, including Zhang Huadong, Director of the Chongqing CDC; Ji Hengqing and Wang Qing, Deputy Directors; and Zheng Haifa, General Manager of Minhai Bio, along with Liu Jiankai, Executive Deputy General Manager and Director of the R&D Center.

   

At the meeting, the heads of R&D and clinical operations at Minhai Biologics presented the company’s development trajectory, its innovative R&D capabilities, and the progress of key projects’ clinical trials. The Chongqing Center for Disease Control and Prevention outlined its institutional functions, technical strengths, and experience in disease prevention and control. Following the session, with all attendees witnessing, Minhai Biologics and the Chongqing CDC held a signing ceremony for a strategic cooperation agreement. The two parties reached broad consensus on multiple fronts, including vaccine R&D collaboration, support for clinical trials, technical exchanges, talent development, and public education about vaccines. By leveraging their respective strengths, they will seamlessly integrate the company’s R&D and manufacturing expertise with the CDC’s surveillance and prevention experience, jointly advancing the development of China’s vaccine sector.

Looking ahead, the two parties will collaborate closely, continuously deepen their cooperation, strengthen resource sharing and leverage their respective strengths, and work together to make greater contributions to the development of public health initiatives, including infectious disease prevention and control, thereby providing stronger safeguards for public health.

 

 

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09